The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues

Japanese Journal of Clinical Oncology

Volumn 41, Issue 2, 2011, Pages 165-171

  Okayama, Naoko ^a   Nishioka, Mitsuaki ^a   Hazama, Shoichi ^b   Sakai, Kouhei ^b   Suehiro, Yutaka ^b   Maekawa, Masato ^c   Sakamoto, Jun Ichi ^d   Iwamoto, Shigeyoshi ^e   Kato, Takeshi ^f   Mishima, Hideyuki ^g   Oka, Masaaki ^b   Hinoda, Yuji ^a,b  

^a YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^f Minoh City Hospital   (Japan)

^g OSAKA NATIONAL HOSPITAL   (Japan)

Author keywords

Amplicon size; Colorectal cancer; DNA amplificability; FFPE; KRAS test

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; FORMALDEHYDE; IRINOTECAN; K RAS PROTEIN; PARAFFIN;

AMPLICON; ARTICLE; CANCER PATIENT; CANCER TISSUE; COLORECTAL CANCER; DNA EXTRACTION; DNA SEQUENCE; EXON; GENE AMPLIFICATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; MUTATION; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; TISSUE SECTION;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FIXATIVES; FORMALDEHYDE; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TISSUE FIXATION;

EID: 79251634728     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq173     Document Type: Article

References (28)

1. Linardou H, Dahabreh I, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72.
2. Mok T, Wu Y-L, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
3. Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
4. Karapetis C, Khambata-Ford S, Jonker D, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
5. Goeiz S, Hamilton S, Vogelstein B. Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 1985;130:18-26.
6. Dubeau L, Chandler L, Gralow J, Nichols PW, Jones PA. Southern blot analysis of DNA extracted from formalin-fixed pathology specimens. Cancer Res 1986;46:964-9.
7. Ben-Ezra J, Johnson D, Rossi J, Cook N, Wu A. Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. J Histochem Cytochem 1991;39:351-4.
8. Zsikla V, Baumann M, Cathomas G. Effect of buffered formalin on amplification of DNA from paraffin wax embedded small biopsies using real-time PCR. J Clin Pathol 2004;57:654-6.
9. Crisam D, Mattson J. Retrospective DNA analysis using fixed tissue specimens. DNA Cell Biol 1993;12:455-64.
10. Okello J, Zurek J, Devault A, Kuch M, Okwi AL, Sewankambo NK, et al. Comparison of methods in the recovery of nucleic acids from archival formalin-fixed paraffin-embedded autopsy tissues. Anal Biochem 2010;400:110-7.
11. Greer C, Lund J, Manos M. PCR amplification from paraffin-embedded tissues: recommendations on fixatives for long-term storage and prospective studies. PCR Methods Appl 1991;1:46-50.
12. Talaulikar D, Shadbolt B, McNiven M, Dahlstrom JE. DNA amplification from formalin-fixed decalcified paraffin-embedded bone marrow trephine specimens: does the duration of storage matter. Pathology 2008;40:702-6.
13. Adank M, Brogi E, Bogomolniy F, Wadsworth EA, Lafaro KJ, Yee CJ, et al. Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. Fam Cancer 2006;5:337-42.
14. Dedhia P, Tarale S, Dhongde G, Khadapkar R, Das B. Evaluation of DNA extraction methods and real time PCR optimization on formalin-fixed paraffin-embedded tissues. Asian Pac J Cancer Prev 2007;8:55-9.
15. Miething F, Hering S, Hanschke B, Dressler J. Effect of fixation to the degradation of nuclear and mitochondrial DNA in different tissues. J Histochem Cytochem 2006;54;371-4.
16. Hazama S, Nagashima A, Kondo H, Yoshida S, Shimizu R, Araki A, et al. Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci 2010;101:722-7.
17. Hirata H, Hinoda Y, Tanaka Y, Okayama N, Suehiro Y, Kawamoto K, et al. Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 2007;43:231-7.
18. Okayama N, Hamanaka Y, Suehiro Y, Hasui Y, Nakamura J, Hinoda Y. Association of interleukin-10 promoter single nucleotide polymorphisms -819 T/C and-592 A/C with aging. J Gerontol A Biol Sci Med Sci 2005;60:1525-9.
19. Nohara H, Okayama N, Inoue N, Koike Y, Fujimura K, Suehiro Y, et al. Association of the 2173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol 2004;39:242-6.
20. Richman S, Seymour M, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
21. Lie'vre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Makhson A, et al. KRAS Mutations As an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
22. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-7.
23. Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G, et al. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS ONE 2009;4:e7746.
24. Clayton S, Scott F, Walker J, Callaghan K, Haque K, Liloglou T, et al. K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 2000;46:1929-38.
25. Chen CY, Shiesh SC, Wu SJ. Rapid detection of K-ras mutations in bile by peptide nucleic acid-mediated PCR clamping and melting curve analysis: comparison with restriction fragment length polymorphism analysis. Clin Chem 2004;50:481-9.
26. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 2005;7:413-21.
27. Van Krieken J, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008;453:417-31.
28. Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, et al. A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn 2009;11: 543-52.